-

AcureX Therapeutics to Present at Oppenheimer Biotechnology – Emerging Science Summit

SAN CARLOS, Calif.--(BUSINESS WIRE)--AcureX Therapeutics Corporation, a privately-held preclinical-stage biotechnology company focused on developing disease altering therapeutics for neurodegenerative diseases, today announced that it was selected to present at the Oppenheimer Biotechnology – Emerging Science Summit on October 15th, 2021.

Presentation details:

Halting Neurodegeneration with Miro1 Directed Therapies
Presented by: William Shrader, Ph.D., Co-founder and CEO AcureX Therapeutics
Date and time: October 15th, 2021 at 1:30p.m. ET / 10:30a.m. PT

The Oppenheimer Biotechnology – Emerging Science Summit will be held virtually and will feature Stanford University’s SPARK program. Presentations will be given by experts in the fields of oncology, immunology, neurology, and gene therapy, as well as management from several publicly traded companies.

William Shrader, Ph.D. said, “We at AcureX are pleased to be recognized as a leader in an emerging field and we are delighted to share our novel drug discovery approach at this prestigious forum.”

About AcureX Therapeutics

The mission of AcureX Therapeutics is to halt neurodegenerative diseases driven by impaired mitophagy, starting with Parkinson’s Disease. AcureX expects to have one or more late-preclinical therapeutic candidates for Parkinson’s in human trials within two years, followed by candidates for other neurodegenerative diseases. AcureX’s novel approach and founding intellectual property are based on recent discoveries made by the company’s inventor and co-founder, Xinnan Wang MD, Ph.D. AcureX has built a unique target and drug discovery platform to accelerate drug development and de-risk clinical trials with an exclusive license to the founding intellectual property. The AcureX team is led by veteran scientists with a proven track record in CNS drug development and serial life sciences entrepreneurs. For more information, please visit https://www.acurex.com.

Oppenheimer Biotechnology – Emerging Science Summit Registration

To express interest, please contact your Oppenheimer Institutional Salesperson or email Deena Sullivan at Deena.Sullivan@opco.com

Contacts

Ashley Gonzalez, Ph.D.
Info@acurex.com

Industry:

AcureX Therapeutics Corporation

Release Summary
AcureX Therapeutics to present at Oppenheimer Biotechnology – Emerging Science Summit
Release Versions
English

Contacts

Ashley Gonzalez, Ph.D.
Info@acurex.com

More News From AcureX Therapeutics Corporation

Acurex Biosciences to Present at the Michael J. Fox Foundation Parkinson’s Disease Therapeutics Conference

SAN CARLOS, Calif.--(BUSINESS WIRE)--Acurex Biosciences Corporation, a privately-held biopharmaceutical company with a mission to stop neurodegeneration before it starts, has been selected to present at the 15th annual Parkinson’s Disease Therapeutics Conference hosted by the Michael J. Fox Foundation. Presentation Highlights: “De-risking Therapeutic Development: The Power of Mitophagy Biomarkers in PD” Speaker: William Shrader, Ph.D., Co-founder and CEO of Acurex Biosciences Venue: Quorum by C...

Acurex Biosciences Appoints Esteemed Biopharmaceutical Leader Dr. Robert Booth to its Board of Directors

SAN CARLOS, Calif.--(BUSINESS WIRE)--Acurex Biosciences Corporation, a biopharmaceutical company with a mission to stop neurodegeneration before it begins, announces the appointment of renowned biopharmaceutical industry leader Dr. Robert Booth to its Board of Directors. Dr. Booth, distinguished for his invaluable contributions to the biopharmaceutical industry, brings over 30 years of experience in drug discovery, development, and executive leadership. Dr. Booth earned his Ph.D. in biochemistr...

Acurex Biosciences to Present Early Clinical Results Supporting its Novel Parkinson’s Disease Biomarkers at a Michael J. Fox Foundation Biomarkers Workshop

SAN CARLOS, Calif.--(BUSINESS WIRE)--Acurex Biosciences Corporation, a privately-held biopharmaceutical company with a mission to stop neurodegeneration before it starts, has been selected to present early results on its IRB-approved clinical trial for Parkinson’s disease (PD) patients. This longitudinal study evaluates Acurex’s first-in-class non-invasive biomarkers that detect the underlying biology of neurodegenerative disease pathology. Parkinson’s disease is the second most common neurodeg...
Back to Newsroom